First Trimester Contingent Screening for Aneuploidies with Cell-Free Fetal DNA in Singleton Pregnancies - a Swiss Single Centre Experience

Overview

Journal Geburtshilfe Frauenheilkd

Specialty Gynecology & Obstetrics

Date 2024 Jan 5

PMID 38178899

Authors

Alice Proto

Fabienne Trottmann

Sophie Schneider

Sofia Amylidi-Mohr

Florent Badique

Lorenz Risch

Daniel Surbek

Luigi Raio

Beatrice Mosimann

Affiliations

Soon will be listed here.

Abstract

Introduction: Switzerland was amongst the first countries to offer cell-free fetal DNA (cffDNA) testing covered by the health insurance to pregnant women with a risk ≥ 1:1000 for trisomies at first trimester combined screening (FTCS). The aim of this study is to evaluate the implementation of this contingent model in a single tertiary referral centre and its effect on gestational age at diagnosing trisomy 21.

Materials And Methods: Between July 2015 and December 2020 all singleton pregnancies at 11-14 weeks of gestation without major fetal malformation were included and stratified according to their risk at FTCS. Statistical analysis was performed by GraphPad Version 9.1 for Windows.

Results: 4424 pregnancies were included. Of 166 (3.8%) pregnancies with a NT ≥ 3.5 mm and/or a risk ≥ 1:10 at FCTS, 130 (78.3%) opted for direct invasive testing. 803 (18.2%) pregnancies had an intermediate risk, 692 (86.2%) of them opted for cffDNA first. 3455 (78.1%) pregnancies had a risk < 1:1000. 63 fetuses were diagnosed with trisomy 21, 47 (74.6%) directly by invasive procedures after FTCS, 16 (25.4%) by cffDNA first.

Conclusions: Most women choose cffDNA or invasive testing as second tier according to national guidelines. Despite the delay associated with cffDNA testing after FCTS, 75% of all trisomy 21 are still diagnosed in the first trimester with this contingent screening model.

References

Maymon R, Dreazen E, Rozinsky S, Bukovsky I, Weinraub Z, Herman A . Comparison of nuchal translucency measurement and second-trimester triple serum screening in twin versus singleton pregnancies. Prenat Diagn. 1999; 19(8):727-31. DOI: 10.1002/(sici)1097-0223(199908)19:8<727::aid-pd631>3.0.co;2-t. View

Wald N, Kennard A, Hackshaw A, McGuire A . Antenatal screening for Down's syndrome. J Med Screen. 1997; 4(4):181-246. DOI: 10.1177/096914139700400402. View

Minear M, Lewis C, Pradhan S, Chandrasekharan S . Global perspectives on clinical adoption of NIPT. Prenat Diagn. 2015; 35(10):959-67. PMC: 5065727. DOI: 10.1002/pd.4637. View

Nicolaides K, Azar G, Byrne D, Mansur C, Marks K . Fetal nuchal translucency: ultrasound screening for chromosomal defects in first trimester of pregnancy. BMJ. 1992; 304(6831):867-9. PMC: 1882788. DOI: 10.1136/bmj.304.6831.867. View

. Practice Bulletin No. 163: Screening for Fetal Aneuploidy. Obstet Gynecol. 2016; 127(5):e123-e137. DOI: 10.1097/AOG.0000000000001406. View

Christiaens L, Chitty L, Langlois S . Current controversies in prenatal diagnosis: Expanded NIPT that includes conditions other than trisomies 13, 18, and 21 should be offered. Prenat Diagn. 2021; 41(10):1316-1323. DOI: 10.1002/pd.5943. View

Souka A, von Kaisenberg C, Hyett J, Sonek J, Nicolaides K . Increased nuchal translucency with normal karyotype. Am J Obstet Gynecol. 2005; 192(4):1005-21. DOI: 10.1016/j.ajog.2004.12.093. View

Gil M, Galeva S, Jani J, Konstantinidou L, Akolekar R, Plana M . Screening for trisomies by cfDNA testing of maternal blood in twin pregnancy: update of The Fetal Medicine Foundation results and meta-analysis. Ultrasound Obstet Gynecol. 2019; 53(6):734-742. DOI: 10.1002/uog.20284. View

Nicolaides K, Wright D, Poon L, Syngelaki A, Gil M . First-trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell-free DNA testing. Ultrasound Obstet Gynecol. 2013; 42(1):41-50. DOI: 10.1002/uog.12511. View

10.

Bilardo C . The implementation of non-invasive prenatal testing (NIPT) in the Netherlands. J Perinat Med. 2021; 49(8):941-944. DOI: 10.1515/jpm-2021-0290. View

11.

Shear M, Swanson K, Garg R, Jelin A, Boscardin J, Norton M . A systematic review and meta-analysis of cell-free DNA testing for detection of fetal sex chromosome aneuploidy. Prenat Diagn. 2023; 43(2):133-143. PMC: 10268789. DOI: 10.1002/pd.6298. View

12.

Lou S, Petersen O, Jorgensen F, Lund I, Kjaergaard S, Vogel I . National screening guidelines and developments in prenatal diagnoses and live births of Down syndrome in 1973-2016 in Denmark. Acta Obstet Gynecol Scand. 2017; 97(2):195-203. DOI: 10.1111/aogs.13273. View

13.

Gil M, Accurti V, Santacruz B, Plana M, Nicolaides K . Analysis of cell-free DNA in maternal blood in screening for aneuploidies: updated meta-analysis. Ultrasound Obstet Gynecol. 2017; 50(3):302-314. DOI: 10.1002/uog.17484. View

14.

Boon E, Faas B . Benefits and limitations of whole genome versus targeted approaches for noninvasive prenatal testing for fetal aneuploidies. Prenat Diagn. 2013; 33(6):563-8. DOI: 10.1002/pd.4111. View

15.

Trottmann F, Mollet A, Amylidi-Mohr S, Surbek D, Raio L, Mosimann B . Integrating Combined First Trimester Screening for Preeclampsia into Routine Ultrasound Examination. Geburtshilfe Frauenheilkd. 2022; 82(3):333-340. PMC: 8893983. DOI: 10.1055/a-1534-2599. View

16.

Gadsboll K, Petersen O, Gatinois V, Strange H, Jacobsson B, Wapner R . Current use of noninvasive prenatal testing in Europe, Australia and the USA: A graphical presentation. Acta Obstet Gynecol Scand. 2020; 99(6):722-730. DOI: 10.1111/aogs.13841. View

17.

Oepkes D, Page-Christiaens G, Bax C, Bekker M, Bilardo C, Boon E . Trial by Dutch laboratories for evaluation of non-invasive prenatal testing. Part I-clinical impact. Prenat Diagn. 2016; 36(12):1083-1090. PMC: 5214231. DOI: 10.1002/pd.4945. View

18.

Lo Y, Tein M, Lau T, Haines C, Leung T, Poon P . Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis. Am J Hum Genet. 1998; 62(4):768-75. PMC: 1377040. DOI: 10.1086/301800. View

19.

Eiben B, Glaubitz R, Winkler T, Merz E . First-Trimester Screening in Germany After the Introduction of NIPT as a General Health Insurance Benefit. Ultraschall Med. 2023; 44(3):327-328. DOI: 10.1055/a-2028-8108. View

20.

Gil M, Revello R, Poon L, Akolekar R, Nicolaides K . Clinical implementation of routine screening for fetal trisomies in the UK NHS: cell-free DNA test contingent on results from first-trimester combined test. Ultrasound Obstet Gynecol. 2015; 47(1):45-52. DOI: 10.1002/uog.15783. View